Cytokinetics said on Tuesday its experimental heart disease drug significantly improved patients' ability to exercise compared to standard-of-care treatment in a late-stage study, sending shares of ...

Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted ...

Cytokinetics said on Tuesday its experimental heart disease drug significantly improved patients' ability to exercise compared to standard-of-care treatment in a late-stage study. The keenly watched ...

Cytokinetics has shared positive top-line results from a late-stage study of its investigational oral cardiac myosin ...

The FDA extended aficamten's review by three months for REMS safety program finalization, causing Cytokinetics' stock to drop over 11%. The REMS requirement is expected and does not indicate ...

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) ...

On Wednesday, 21 May 2025, Cytokinetics (NASDAQ:CYTK) participated in the RBC Capital Markets Global Healthcare Conference 2025, providing a comprehensive update on its drug development pipeline.

Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patientswith Mild and Moderate-to-Severe Symptoms, and ...

SOUTH SAN FRANCISCO, Calif. (AP) — Cytokinetics Inc. (CYTK) on Tuesday reported a loss of $161.4 million in its first quarter. On a per-share ...

May 13 (Reuters) - Cytokinetics (CYTK.O), opens new tab said on Tuesday its experimental heart disease drug significantly improved patients' ability to exercise compared to standard-of-care ...